Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 13/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15829146 | 0.94 | PLA2G7 (0.40) | PLA2G7GPR84PDE4A | |
| SCHEMBL14663613 | 0.93 | PLA2G7 (0.42) | PLA2G7GPR84PDE4A | |
| SCHEMBL15814330 | 0.88 | PLA2G7 (0.45) | PLA2G7GPR84PDE4A | |
| SCHEMBL14656354 | 0.86 | PLA2G7 (0.42) | PLA2G7GPR84PDE4A | |
| SCHEMBL15813634 | 0.85 | GPR84 (0.40) | PLA2G7GPR84PDE4A | |
| SCHEMBL14663571 | 0.84 | PLA2G7 (0.42) | PLA2G7GPR84PDE4A | |
| SCHEMBL14667659 | 0.83 | PLA2G7 (0.42) | PLA2G7GPR84PDE4A | |
| SCHEMBL14663566 | 0.81 | GPR84 (0.43) | PLA2G7GPR84PDE4A | |
| SCHEMBL14670123 | 0.81 | PLA2G7 (0.48) | PLA2G7GPR84 | |
| SCHEMBL14670039 | 0.81 | PLA2G7 (0.49) | PLA2G7GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | PLA2G4A, PLA2G4C, PLA2G4B | PLA2G7 9/4885GPR84 904/4885PDE4A 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.